SCHEMBL4147167

SCHEMBL4147167

N#Cc1ccc(N(Cc2nc(-c3cccc(C(F)(F)F)c3)no2)CC(F)(F)F)cc1C(F)(F)F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 2/20 0.44
NR1H2 P55055 1/20 0.41
NR1H3 Q13133 1/20 0.41
AR P10275 3/20 0.41
FFAR1 O14842 2/20 0.40
TP53 P04637 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
NR1H4 Q96RI1 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
PGR P06401 1/20 0.39
CASP3 P42574 1/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
GAA P10253 1/20 0.38
HPGD P15428 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HSD17B10 Q99714 1/20 0.38
HDAC1 Q13547 2/20 0.38
HDAC6 Q9UBN7 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4158085 0.91 S1PR1 (0.41) S1PR1ARTP53NPSR1PGR
SCHEMBL4150659 0.90 AR (0.48) S1PR1ARNPC1RAB9APGR
SCHEMBL4145663 0.89 S1PR1 (0.44) S1PR1ARPGRSMN1; SMN2HDAC1
SCHEMBL4146941 0.86 ALDH1A1 (0.44) S1PR1ARNPC1RAB9AALDH1A1
SCHEMBL4150665 0.86 HDAC2 (0.47) ARNPC1RAB9APGRSMN1; SMN2
SCHEMBL4153657 0.85 AR (0.40) S1PR1ARNPC1RAB9APGR
SCHEMBL4156505 0.85 RAB9A (0.41) S1PR1ARTP53NPC1RAB9A
SCHEMBL4144463 0.84 NR1H2 (0.45) NR1H2NR1H3ARNPC1RAB9A
SCHEMBL4137720 0.84 NR1H2 (0.46) NR1H2NR1H3ARTP53NPC1
SCHEMBL4146890 0.82 AR (0.43) S1PR1ARPGRCASP3SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170907-A1 Chemical Compounds SMITHKLINE BEECHAM CORPORATION (US) 2009-07-02 US claimed
EP-1888512-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2008-02-20 EP claimed
WO-2006133216-A2 4-SUBSTITUTED ARYLAMINE DERIVATIVES AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS SMITHKLINE BEECHAM CORPORATION (US) 2006-12-14 WO claimed
US-20090170907-A1 Chemical Compounds SMITHKLINE BEECHAM CORPORATION (US) 2009-07-02 US disclosed
US-20090170907-A1 Chemical Compounds SMITHKLINE BEECHAM CORPORATION (US) 2009-07-02 US disclosed
EP-1888512-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2008-02-20 EP disclosed
WO-2006133216-A2 4-SUBSTITUTED ARYLAMINE DERIVATIVES AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS SMITHKLINE BEECHAM CORPORATION (US) 2006-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170907-A1 Chemical Compounds NR3C2, NR5A1, NR3C1 S1PR1 781/4885NR1H2 61/4885NR1H3 57/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.